Cullinan Therapeutics Inc. (NASDAQ:CGEM) is one of the stocks that will double in 2026. On December 10, Clear Street raised the firm’s price target on Cullinan Therapeutics to $33 from $22 with a Buy ...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Cullinan Therapeutics Inc (Symbol: CGEM), where a total of 5,055 contracts have traded so ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability ...

NADIM AHMED, the President and CEO of $CGEM ($CGEM), sold 8,400 shares of the company on 12-24-2024. We received data on the trade from a recent SEC filing. This was ...

Fintel reports that on February 2, 2026, Guggenheim initiated coverage of Cullinan Therapeutics (NasdaqGS:CGEM) with a Buy recommendation. Analyst Price Forecast Suggests 160.41% Upside As of January ...

CGEM has an interesting “modality‑agnostic” approach that focuses on targets first, then models yield the most promising candidates. This way, CGEM has built a relatively well-diversified oncology and ...

Cullinan Therapeutics focuses on unaddressed or unmet needs in oncology and autoimmune conditions. In particular, Zipalertinib and CLN-978 stand out as its most promising product candidates.

The latest price target for Cullinan Therapeutics (NASDAQ:CGEM) was reported by Wedbush on December 9, 2025. The analyst firm set a price target for $34.00 expecting CGEM to rise to within 12 months ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Fintel reports that on February 17, 2026, Citigroup initiated coverage of Cullinan Therapeutics (NasdaqGS:CGEM) with a Buy recommendation. Analyst Price Forecast Suggests 184.02% Upside As of February ...